Released Nov 4, 2026, after the close
10-Q filed Nov 4, 2026, 35 days after period end · 0001628280-26-070259
What the release said
Total revenue for the third quarter of 2026 was $53.2 million, a 2% increase compared to the third quarter of 2025.
Cytek Biosciences reported total revenue of $53.2 million for the third quarter of 2026, a 2% increase compared to the third quarter of 2025.¶1¶2
GAAP gross profit was $31.2 million for the third quarter of 2026, a 13% increase, with GAAP gross profit margin of 59% compared to 53% in the third quarter of 2025.¶3
Operating expenses were $39.6 million for the third quarter of 2026, and net loss was $6.1 million compared to a net loss of $5.5 million in the third quarter of 2025.¶4¶5
Cytek Biosciences is maintaining the midpoint of its full year 2026 revenue outlook and narrowing the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates.¶6
Cash, cash equivalents, restricted cash and marketable securities totaled $256.3 million as of September 30, 2026, compared to $262.0 million as of June 30, 2026.¶7
- Total revenue, third quarter 2026
- $53.2 million Compared to the third quarter of 2025, a 2% increase¶1
- GAAP gross profit, third quarter 2026
- $31.2 million A 13% increase compared to the third quarter of 2025¶3
- Net loss, third quarter 2026
- $6.1 million Compared to a net loss of $5.5 million in the third quarter of 2025¶5
- Full year 2026 total revenue outlook
- $208 million to $211 million Range narrowed; midpoint maintained, assuming no change in current foreign currency exchange rates¶6
- Cash, cash equivalents, restricted cash and marketable securities
- $256.3 million As of September 30, 2026, compared to $262.0 million as of June 30, 2026¶7
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $53.23M | $52.29M | $51.50M | $48.00M |
| Net Income | -$6.10M | -$5.48M | $941.00K | -$6.46M |
| EPS Diluted | -$0.05 | -$0.04 | $0.01 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR